Redwire Awarded Contract from Aspera Biomedicines to Investigate Cutting-Edge Cancer Treatment in Space
MWN-AI** Summary
Redwire Corporation (NYSE: RDW), a forefront player in space infrastructure, has been awarded a contract from Aspera Biomedicines to conduct pioneering cancer research utilizing its Pharmaceutical In-space Laboratory (PIL-BOX) technology. This collaboration will focus on advancing Aspera's investigational cancer treatment, rebecsinib, an FDA-approved small molecule ADAR1 inhibitor entering human trials. Research has indicated that the ADAR1 protein is upregulated in cancer stem cells, contributing to the aggressive progression of certain cancers. Previous spaceflight experiments suggested that rebecsinib can inhibit ADAR1 expression, effectively serving as a “kill switch” for cancer stem cells.
In the upcoming mission, Aspera's team will investigate the crystal structure of the ADAR1p150 protein in various states, aiming to uncover insights that could lead to the development of new drug formulations and a broader range of potential ADAR1 inhibitors. Redwire’s President of In-Space Industries, John Vellinger, expressed enthusiasm for the project, highlighting its potential to contribute significantly to cancer research.
Aspera's co-founder, Catriona Jamieson, acknowledged the importance of this partnership, stating it leverages NASA's infrastructure and microgravity advantages for enhanced protein crystallization processes. This unique collaboration aims to create small molecule inhibitors that address cancer stem cell cloning and immune evasion—critical factors in cancer relapse.
The PIL-BOX platform has already proven effective, with prior studies in collaboration with major pharmaceutical companies targeting various diseases. Aspera's innovative cancer treatment research is set to launch later this year, representing a notable intersection of space exploration and medical advancement. Redwire continues to position itself as a key enabler of groundbreaking discoveries in human health through its advanced space technology.
MWN-AI** Analysis
Redwire Corporation (NYSE: RDW), a key player in the emerging space economy, has recently secured a contract from Aspera Biomedicines to utilize its Pharmaceutical In-space Laboratory (PIL-BOX) technology for groundbreaking cancer treatment research. This partnership aligns Redwire with innovative biopharmaceutical advancements and positions it favorably within the burgeoning intersection of space exploration and healthcare.
The contract enables Aspera to leverage microgravity conditions aboard the International Space Station to investigate rebecsinib, an FDA-approved small molecule inhibitor targeting the ADAR1 protein, linked to cancer stem cell proliferation. This research has significant implications, particularly as the ability to crystalize proteins could lead to the development of enhanced cancer therapies, including potential "kill switches" that halt cancer progression.
Investors should view this development as a catalyst for Redwire’s growth, particularly given its strategic alignments with NASA and industry leaders. With a proven track record through the PIL-BOX, which has previously contributed to important research initiatives alongside major pharmaceutical companies, Redwire is establishing itself not just as a space infrastructure provider but as a vital participant in life sciences innovation.
Aspera's focus on utilizing microgravity to enhance drug development demonstrates the increasing relevance of space in healthcare solutions. The collaborative nature of this endeavor, particularly the involvement of NASA and the California Institute for Regenerative Medicine, may yield transformative outcomes for cancer treatment.
Demand for innovative healthcare solutions remains robust amid increasing global health concerns. Redwire's spinoffs from this project could attract further partnerships with other pharmaceutical firms seeking to explore the benefits of space research. Therefore, maintaining a watchful eye on both Redwire’s operational performance and the outcomes of Aspera's research is advisable. The potential for substantial advances in both companies could reflect positively in their stock performance in the upcoming quarters.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Redwire Corporation (NYSE: RDW), a leader in space infrastructure for the next generation space economy, announced today that it has been awarded a contract from Aspera Biomedicines, Inc. (Aspera), a pharmaceutical company specializing in the development of cancer stem cell targeted therapies, to conduct space-based research and analysis on a new cancer treatment using Redwire’s Pharmaceutical In-space Laboratory (PIL-BOX) technology.
Aspera will use this mission to advance development of rebecsinib, a small molecule ADAR1 inhibitor recently approved by the U.S. Food and Drug Administration to begin first-in-human trials. On Earth, scientists have noted an upregulation – or increased rate of expression – of the ADAR1 protein in cancer stem cells as being linked to the accelerated progression of some types of cancer. Researchers at Aspera have analyzed data from two previous spaceflight experiments that showed that rebecsinib can inhibit expression of ADAR1, halting the progression of cancer stem cell propagation in triple-negative breast cancer organoid models. Results from Aspera’s prior experiments indicate that rebecsinib could behave as a cancer “kill switch.”
On this mission, Aspera researchers will analyze the crystal structure of ADAR1p150 with and without rebecsinib or intermediates. The results of this analysis could enhance opportunities to develop new drug formulations and a broader array of ADAR1 inhibitors.
“Redwire is excited to facilitate critical space research for Aspera Biomedicines’ cutting-edge cancer treatment that could have major implications in the global fight against cancer,” said Redwire’s President of In-Space Industries John Vellinger. “Redwire's PIL-BOX technology continues to be a critical resource for enabling game-changing discoveries to advance human health.”
“At Aspera, it is a privilege to partner with our industrious and innovative colleagues at NASA, CASIS, and Redwire, through a NASA In Space Phase 2 biomanufacturing grant, to utilize microgravity to enhance and accelerate protein crystallization of the target of our FDA IND-approved small molecule inhibitor of the cancer cloning and immune evasion gene, ADAR1p150,” said Aspera’s co-founder, Catriona Jamieson. “We anticipate that this unique partnership combined with the science accelerating environment of the NASA International Space Station will extend the spectrum of small molecule ‘cancer kill switches’ aimed at preventing cancer stem cell cloning and immune evasion properties that drive relapse, the leading cause of cancer-related mortality.”
With 28 units flown and processed to date, PIL-BOX is the premier platform for pharmaceutical researchers, leveraging the microgravity environment to grow small-batch crystals of protein-based pharmaceuticals and other key pharmaceutically relevant molecules.
Previous PIL-BOX investigations conducted with partners including Bristol Myers Squibb, ExesaLibero Pharma, Eli Lilly and Company, and Butler University have focused on unlocking insights to improve treatments for cardiovascular disease, obesity, and diabetes.
The Aspera cancer treatment investigation is slated to launch later this year.
About Redwire
Redwire Corporation (NYSE:RDW) is a global space infrastructure and innovation company enabling civil, commercial, and national security programs. Redwire’s proven and reliable capabilities include avionics, sensors, power solutions, critical structures, mechanisms, radio frequency systems, platforms, missions, and microgravity payloads. Redwire combines decades of flight heritage and proven experience with an agile and innovative culture. Redwire’s approximately 750 employees working from 17 facilities located throughout the United States and Europe are committed to building a bold future in space for humanity, pushing the envelope of discovery and science while creating a better world on Earth. For more information, please visit redwirespace.com .
About Aspera Biomedicines
Aspera Biomedicines was founded in San Diego in 2020 to develop cancer stem cell targeting small molecule inhibitors together with platform technologies that detect normal stem cell fitness and precancer and cancer stem cell development. With the California Institute for Regenerative Medicine (CIRM), NASA, and angel investor support, Aspera is the first company to develop an FDA IND approved small molecule inhibitor of ADAR1 splicing for myelofibrosis and acute myeloid leukemia that may also have implications for preventing recurrence and immune evasion in 20 cancers. By using microgravity to accelerate tumor growth with NASA and CASIS supported platforms as well as a dedicated collaborative partnership with Axiom Space, Aspera aims to investigate an expanded group of tumor indications for rebecsinib in patient derived tumor organoids to prevent the leading causes of cancer mortality—therapeutic resistance-related recurrence and metastases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250603406669/en/
Media Contacts:
Emily Devine
Emily.Devine@redwirespace.com
305-632-9137
Investors:
investorrelations@redwirespace.com
904-425-1431
Aspera:
kmack@asperabio.com
FAQ**
How does the partnership between Redwire Corporation (NYSE: RDW) and Aspera Biomedicines leverage microgravity research to potentially enhance the efficacy of rebecsinib as a cancer treatment?
What implications could the findings from Redwire Corporation RDW's Pharmaceutical In-space Laboratory (PIL-BOX) research have on the future development of ADAR1 inhibitors in cancer therapies?
Given the successful history of PIL-BOX investigations with other pharmaceutical companies, how might Redwire Corporation RDW attract more partnerships in the biopharmaceutical space?
What strategies does Redwire Corporation RDW plan to implement to scale and commercialize the advances made from this collaboration with Aspera in the field of cancer research?
**MWN-AI FAQ is based on asking OpenAI questions about Redwire Corporation (NYSE: RDW).
NASDAQ: RDW
RDW Trading
-1.94% G/L:
$14.15 Last:
34,319,116 Volume:
$13.73 Open:
